What is new in the 2023 AHA/ACC multisociety guideline on chronic coronary disease?
Gespeichert in:
| Veröffentlicht in: | European heart journal. Cardiovascular pharmacotherapy 2023-12, Vol.9 (8), p.673-678 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 678 |
|---|---|
| container_issue | 8 |
| container_start_page | 673 |
| container_title | European heart journal. Cardiovascular pharmacotherapy |
| container_volume | 9 |
| creator | Gragnano, Felice De Sio, Vincenzo Calabrò, Paolo |
| description | |
| doi_str_mv | 10.1093/ehjcvp/pvad066 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2866377986</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A785088543</galeid><oup_id>10.1093/ehjcvp/pvad066</oup_id><sourcerecordid>A785088543</sourcerecordid><originalsourceid>FETCH-LOGICAL-c436t-9634e1f5ab4d763ad9824178f2ef27398e8bb142fd1c34b310a2a7c681337c273</originalsourceid><addsrcrecordid>eNqF0c9LwzAUB_AgipPp1aMEvOhhLj_aJD1JGf4CwYOKx5Cmr1ukbWrTTvbfG9n0JEgOL4TPeyT5InRKyRUlGZ_D6t2uu3m3NiURYg8dMZKmM6GSdP93z-UEnYTwTgihQgmm-CGacCkZF0Qeoee3lRmwC7iFT-xaPKwAM8I4zu_zeb5Y4GasBxe8dTBs8HJ0JdSuBexbbFe9b53F1sdq-g0uXQAT4PoYHVSmDnCyq1P0envzsrifPT7dPSzyx5lNuBhmmeAJ0Co1RVJKwU2ZKZZQqSoGFZM8U6CKgiasKqnlScEpMcxIKxTlXNoopuhiO7fr_ccIYdCNCxbq2rTgx6CZEiK-NFMi0vMtXZoatGsrP_TGfnOdS5USpdKER3X1h4qrhMZZ30Ll4vlfDbb3IfRQ6a53TfwLTYn-jkhvI9K7iGLD2e7KY9FA-ct_Aongcgv82P037Auq25lF</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2866377986</pqid></control><display><type>article</type><title>What is new in the 2023 AHA/ACC multisociety guideline on chronic coronary disease?</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>PubMed Central</source><creator>Gragnano, Felice ; De Sio, Vincenzo ; Calabrò, Paolo</creator><creatorcontrib>Gragnano, Felice ; De Sio, Vincenzo ; Calabrò, Paolo</creatorcontrib><identifier>ISSN: 2055-6837</identifier><identifier>EISSN: 2055-6845</identifier><identifier>DOI: 10.1093/ehjcvp/pvad066</identifier><identifier>PMID: 37723607</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Associations, institutions, etc ; Atherosclerosis ; Cardiology ; Cardiovascular Diseases ; Clopidogrel ; Coronary Artery Disease - diagnosis ; Coronary Artery Disease - therapy ; Dapagliflozin ; Evidence-based medicine ; Heart failure ; Humans ; Ivabradine ; Societies ; Trimetazidine ; Type 2 diabetes</subject><ispartof>European heart journal. Cardiovascular pharmacotherapy, 2023-12, Vol.9 (8), p.673-678</ispartof><rights>The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. 2023</rights><rights>COPYRIGHT 2023 Oxford University Press</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c436t-9634e1f5ab4d763ad9824178f2ef27398e8bb142fd1c34b310a2a7c681337c273</citedby><cites>FETCH-LOGICAL-c436t-9634e1f5ab4d763ad9824178f2ef27398e8bb142fd1c34b310a2a7c681337c273</cites><orcidid>0000-0002-6943-278X ; 0000-0002-5018-830X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,1579,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37723607$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gragnano, Felice</creatorcontrib><creatorcontrib>De Sio, Vincenzo</creatorcontrib><creatorcontrib>Calabrò, Paolo</creatorcontrib><title>What is new in the 2023 AHA/ACC multisociety guideline on chronic coronary disease?</title><title>European heart journal. Cardiovascular pharmacotherapy</title><addtitle>Eur Heart J Cardiovasc Pharmacother</addtitle><subject>Associations, institutions, etc</subject><subject>Atherosclerosis</subject><subject>Cardiology</subject><subject>Cardiovascular Diseases</subject><subject>Clopidogrel</subject><subject>Coronary Artery Disease - diagnosis</subject><subject>Coronary Artery Disease - therapy</subject><subject>Dapagliflozin</subject><subject>Evidence-based medicine</subject><subject>Heart failure</subject><subject>Humans</subject><subject>Ivabradine</subject><subject>Societies</subject><subject>Trimetazidine</subject><subject>Type 2 diabetes</subject><issn>2055-6837</issn><issn>2055-6845</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0c9LwzAUB_AgipPp1aMEvOhhLj_aJD1JGf4CwYOKx5Cmr1ukbWrTTvbfG9n0JEgOL4TPeyT5InRKyRUlGZ_D6t2uu3m3NiURYg8dMZKmM6GSdP93z-UEnYTwTgihQgmm-CGacCkZF0Qeoee3lRmwC7iFT-xaPKwAM8I4zu_zeb5Y4GasBxe8dTBs8HJ0JdSuBexbbFe9b53F1sdq-g0uXQAT4PoYHVSmDnCyq1P0envzsrifPT7dPSzyx5lNuBhmmeAJ0Co1RVJKwU2ZKZZQqSoGFZM8U6CKgiasKqnlScEpMcxIKxTlXNoopuhiO7fr_ccIYdCNCxbq2rTgx6CZEiK-NFMi0vMtXZoatGsrP_TGfnOdS5USpdKER3X1h4qrhMZZ30Ll4vlfDbb3IfRQ6a53TfwLTYn-jkhvI9K7iGLD2e7KY9FA-ct_Aongcgv82P037Auq25lF</recordid><startdate>20231214</startdate><enddate>20231214</enddate><creator>Gragnano, Felice</creator><creator>De Sio, Vincenzo</creator><creator>Calabrò, Paolo</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6943-278X</orcidid><orcidid>https://orcid.org/0000-0002-5018-830X</orcidid></search><sort><creationdate>20231214</creationdate><title>What is new in the 2023 AHA/ACC multisociety guideline on chronic coronary disease?</title><author>Gragnano, Felice ; De Sio, Vincenzo ; Calabrò, Paolo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c436t-9634e1f5ab4d763ad9824178f2ef27398e8bb142fd1c34b310a2a7c681337c273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Associations, institutions, etc</topic><topic>Atherosclerosis</topic><topic>Cardiology</topic><topic>Cardiovascular Diseases</topic><topic>Clopidogrel</topic><topic>Coronary Artery Disease - diagnosis</topic><topic>Coronary Artery Disease - therapy</topic><topic>Dapagliflozin</topic><topic>Evidence-based medicine</topic><topic>Heart failure</topic><topic>Humans</topic><topic>Ivabradine</topic><topic>Societies</topic><topic>Trimetazidine</topic><topic>Type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gragnano, Felice</creatorcontrib><creatorcontrib>De Sio, Vincenzo</creatorcontrib><creatorcontrib>Calabrò, Paolo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European heart journal. Cardiovascular pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gragnano, Felice</au><au>De Sio, Vincenzo</au><au>Calabrò, Paolo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>What is new in the 2023 AHA/ACC multisociety guideline on chronic coronary disease?</atitle><jtitle>European heart journal. Cardiovascular pharmacotherapy</jtitle><addtitle>Eur Heart J Cardiovasc Pharmacother</addtitle><date>2023-12-14</date><risdate>2023</risdate><volume>9</volume><issue>8</issue><spage>673</spage><epage>678</epage><pages>673-678</pages><issn>2055-6837</issn><eissn>2055-6845</eissn><cop>England</cop><pub>Oxford University Press</pub><pmid>37723607</pmid><doi>10.1093/ehjcvp/pvad066</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-6943-278X</orcidid><orcidid>https://orcid.org/0000-0002-5018-830X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2055-6837 |
| ispartof | European heart journal. Cardiovascular pharmacotherapy, 2023-12, Vol.9 (8), p.673-678 |
| issn | 2055-6837 2055-6845 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2866377986 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); PubMed Central |
| subjects | Associations, institutions, etc Atherosclerosis Cardiology Cardiovascular Diseases Clopidogrel Coronary Artery Disease - diagnosis Coronary Artery Disease - therapy Dapagliflozin Evidence-based medicine Heart failure Humans Ivabradine Societies Trimetazidine Type 2 diabetes |
| title | What is new in the 2023 AHA/ACC multisociety guideline on chronic coronary disease? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T16%3A44%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=What%20is%20new%20in%20the%202023%20AHA/ACC%20multisociety%20guideline%20on%20chronic%20coronary%20disease?&rft.jtitle=European%20heart%20journal.%20Cardiovascular%20pharmacotherapy&rft.au=Gragnano,%20Felice&rft.date=2023-12-14&rft.volume=9&rft.issue=8&rft.spage=673&rft.epage=678&rft.pages=673-678&rft.issn=2055-6837&rft.eissn=2055-6845&rft_id=info:doi/10.1093/ehjcvp/pvad066&rft_dat=%3Cgale_proqu%3EA785088543%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2866377986&rft_id=info:pmid/37723607&rft_galeid=A785088543&rft_oup_id=10.1093/ehjcvp/pvad066&rfr_iscdi=true |